Skip to content
Peptigraph home

SS-31

Mitochondria-targeting peptide. SS-31 is FDA accelerated approval for Barth syndrome (Sep 2025); research-chemical versions are not the approved drug.

Also called:elamipretideForzinity
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusFDA accelerated approval for Barth syndrome (Sep 2025)Not on the WADA Prohibited ListFull legal history

Key facts

Class
Mitochondria-targeting peptide
Also called
elamipretide, Forzinity
Vial sizes sold
10 mg, 25 mg, 50 mg
Community-reported sizes
Half-life
Not found
No published half-life found (PubMed search, 11 Oct 2026)
FDA status
accelerated approval for Barth syndrome (Sep 2025)
Approved
WADA
Not listed
2026 Prohibited List
Everything on SS-31

SS-31 guides

Vial and dose sizes
Researched for

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

SS-31: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
EnergyNot in our ledgerNot in our ledger10Human RCT evidence, 4 of 4Orphanet journal of rare diseases 2024, PMID 39574155
Heart healthNot in our ledgerNot in our ledger3Human RCT evidence, 4 of 4Circulation. Heart failure 2017, PMID 29217757
Muscle growthNot in our ledgerNot in our ledger0No graded study for this goal
SleepNot in our ledgerNot in our ledger0No graded study for this goal

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

SS-31 is elamipretide, now approved for one rare disease

The Forzinity label calls it a mitochondrial cardiolipin binder, and Drugs@FDA lists the brand under elamipretide.[14]

The labelled use is improving muscle strength in adult and pediatric Barth syndrome patients weighing at least 30 kg.[14]

Strongest finding and failures

In the Barth syndrome randomized trial, neither primary endpoint was met in part 1.[15]

A primary mitochondrial myopathy trial did not meet its primary walking or fatigue endpoints.[16]

In dry age-related macular degeneration, a phase 2 trial did not reach statistical significance on its primary end points.[4]

Regulatory path

FDA lists elamipretide as an approved prescription solution; the cached record shows the brand Forzinity.[2]

A UK emc search for elamipretide found no product.[17]

Compared with

Common stacks

SS-31 is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.

Common questions

Is SS-31 FDA approved?

SS-31 is FDA accelerated approval for Barth syndrome (Sep 2025). Products sold as research chemicals are not the approved drug and are not checked by the FDA.

How much water goes in a 10 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

What is SS-31?

Another name for elamipretide, a mitochondrial cardiolipin binder approved for Barth syndrome.[14]

What does SS-31 do?

In Barth syndrome, an open-label extension reported significant walk-distance improvements; blinded trials in other conditions did not meet primary endpoints.[18]

Is there an SS-31 nasal spray?

The FDA record lists Forzinity as a solution; no nasal product appears in the cached FDA record.[2]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: Approved by FDA as Forzinity (elamipretide), Stealth BioTherapeutics, original approval 19 Sept 2025, under accelerated approval to improve muscle strength in Barth syndrome (label quote).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  4. 4ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.Ophthalmology science · 2025PMID 39605874Accessed 2 Oct 2026
  5. 5PubMed search: (elamipretide[tiab] OR Bendavia[tiab] OR "MTP-131"[tiab] OR Forzinity[tiab] OR (("SS-31"[tiab] OR SS31[tiab]) AND (peptide*[tiab] OR mitochondri*[tiab] OR cardiolipin[tiab] OR Szeto[tiab]))) (526 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: (elamipretide[tiab] OR Bendavia[tiab] OR "MTP-131"[tiab] OR Forzinity[tiab] OR (("SS-31"[tiab] OR SS31[tiab]) AND (peptide*[tiab] OR mitochondri*[tiab] OR cardiolipin[tiab] OR Szeto[tiab]))) AND (randomized[tiab] OR trial[tiab] OR patients[tiab]) (133 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: (elamipretide[tiab] OR Bendavia[tiab] OR "MTP-131"[tiab] OR Forzinity[tiab] OR (("SS-31"[tiab] OR SS31[tiab]) AND (peptide*[tiab] OR mitochondri*[tiab] OR cardiolipin[tiab] OR Szeto[tiab]))) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: elamipretide[tiab] AND (TAZPOWER[tiab] OR "Barth syndrome"[tiab]) AND (randomized[tiab] OR crossover[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: elamipretide[tiab] AND (macular[tiab] OR "geographic atrophy"[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: elamipretide[tiab] AND (fibromyalgia[tiab] OR fatigue[tiab] OR "chronic pain"[tiab]) (19 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.Orphanet journal of rare diseases · 2024PMID 39574155Accessed 2 Oct 2026
  12. 12Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.Circulation. Heart failure · 2017PMID 29217757Accessed 2 Oct 2026
  13. 13PubMed search: (elamipretide[tiab] OR Bendavia[tiab] OR "MTP-131"[tiab] OR Forzinity[tiab] OR (("SS-31"[tiab] OR SS31[tiab]) AND (peptide*[tiab] OR mitochondri*[tiab] OR cardiolipin[tiab] OR Szeto[tiab]))) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (77 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  14. 14FORZINITY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  15. 15A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.Genetics in medicine : official journal of the American College of Medical Genetics · 2021PMID 33077895Accessed 2 Oct 2026
  16. 16Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.Neurology · 2023PMID 37268435Accessed 2 Oct 2026
  17. 17emc (UK) search: elamipretideElectronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026
  18. 18Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.Genetics in medicine : official journal of the American College of Medical Genetics · 2024PMID 38602181Accessed 2 Oct 2026

Found an error? Report a correction.